ReviewReviews in endocrine & metabolic disorders2021
Chemotherapy in NEN: still has a role?
Review in Reviews in endocrine & metabolic disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Predictive factors for efficacy of oxaliplatin-based chemotherapy in advanced well-differentiated neuroendocrine tumors: an observational cohort study and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- The Use of Adjunct Therapies with Surgery for Gastroenteropancreatic Neuroendocrine Tumors: Indications, Timing, and Outcomes.Biomedicines · 2026Review
- Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms.Annals of surgical oncology · 2026Article
- Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Challenge and Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Visualized Clinical-Radiomics Model Based on Non-Contrast Computed Tomography for Predicting Efficacy of Surufatinib in Hepatic Metastases of Neuroendocrine Neoplasms.Cancer medicine · 2026Article
- Clinicopathologic features and long term prognosis of early onset gastroenteropancreatic neuroendocrine tumors.Discover oncology · 2026Article
- The impact of radioligand therapy on prognosis in patients with lung neuroendocrine tumors.Frontiers in endocrinology · 2026Article
- From diagnosis to treatment: navigating the course for pancreatic neuroendocrine neoplasms.Annals of medicine · 2025Review
- Prognostic Role of Inflammatory Biomarkers in Gastrointestinal Neuroendocrine Neoplasms: A Cross-Sectional Study.Health science reports · 2025Article
- Review
- Rare epithelial gastric cancers: a review of the current treatment knowledge.Therapeutic advances in medical oncology · 2025Review
- Clinical management and prognostic determinants of gallbladder neuroendocrine carcinoma: a single-institutional analysis of 31 cases.Frontiers in oncology · 2025Article
- Clinical characteristics and survival outcomes of extrapulmonary neuroendocrine carcinomas: a retrospective study.Frontiers in endocrinology · 2025Article
- High incidence and poor prognosis of bone metastases in functioning small intestinal neuroendocrine tumors.Frontiers in endocrinology · 2025Article
- Critical considerations for the management of gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms and pure neuroendocrine carcinomas.World journal of gastrointestinal oncology · 2024Article
- An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.International journal of molecular sciences · 2024Review
- Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?Endocrine reviews · 2023Review
- Neuroendocrine Neoplasms of the Gastrointestinal Tract versus Neuroendocrine Neoplasms of the Gynaecological Tract-Comparison of the Risk Factors and Non-Surgical Treatment Efficacy.International journal of molecular sciences · 2023Review
- Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review.Journal of clinical medicine · 2023Review
- Personalized functional profiling usingCancer biology & therapy · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine neoplasms (NENs) comprise a broad spectrum of tumors with widely variable biological and clinical behavior. Primary tumor site, extent of disease, tumor differentiation and expression of so matostatin receptors, proliferation and growth rates are the major prognostic factors that determine the therapeutic strategy. Treatment options for advanced disease have considerably expanded in recent years, particularly for well differentiated tumors (NETs). Novel drugs approved over the past decade in this context include somatostatin analogues and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.